The 9th China International Import Expo (CIIE)is being held at the National Exhibition and Convention Center (Shanghai). The medical equipment and healthcare products exhibition areahas reached a record size, with 16 of the world's top 20 pharmaceutical companies participating, alongside all three of the world's leading medical imaging manufacturers and all three of the top radiotherapy equipment makers. Over the past nine years, multinational pharmaceutical companies have shifted their strategy from bringing global innovations to the Chinese market to innovating in China, co-creating with China and taking Chinese innovation to the world. A number of innovative products have made the transition from exhibition showcases to commercial products.

A range of innovative products makes theirdebut at the CIIE

Siemens Healthineersis participating in the CIIE for the ninth consecutive year, bringing nearly 20 innovative products and solutions. The Halcyon Evolve intelligent radiotherapy platformis making its global debut, while its photon-counting CT-guided PCI (percutaneous coronary intervention) solutionis being presented in China for the first time. The ARTIS genio floor systemis making its Asian debut. Novartisis showcasing innovations across four therapeutic areas and five technology platforms, including several therapies that are the first of their kind globally. Its investigational immunology drugIanalumab is being presented in China for the first time. It is a fully human monoclonal antibody that targets B cells. Rocheis marking its 100th anniversary of serving China. It recreates an old pharmacy from a century ago at the venue and presents nearly 100 exhibits for debut shows, including giredestrantand Gazyva.

Multinational companies continue to increase investment in China

Bayer has signed strategic cooperation agreements with Sirio Pharma, Jointown Pharmaceutical Group, Ruoyuchenand Shanghai Pharmaceuticals Holding. Novartis has more than 100 clinical research projects underway in China. From 2026 onward, 100% of its new drug registrations in China have been synchronizedwith global filings. Its new Changping plant with an investment of around 1.5 billion yuan has broken ground, and the radioligand therapy manufacturing sitein Haiyanworth roughly 600 million yuan will go into operation in 2027. Roche's Shanghai base, with an investment of 2.04 billion yuan, is the first local large-molecule antibodymanufacturing site built by a multinational pharma firm in China. It will be used to manufacture Vabysmo (faricimab).

全球前沿药械集中首发首秀，外企深耕本土共筑健康中国

第九届中国国际进口博览会在国家会展中心（上海）举办。医疗器械及医药保健展区面积创历届新高：全球前20药企16家参展，前三大影像、放疗设备企业悉数到场。9年来，跨国药企在华战略从 “引入中国”转向“在中国创新、与中国共创、从中国走向全球”，多款创新产品实现从“展品”到“商品”的跨越。

多款创新成果集中亮相进博会

西门子医疗连续9年参展，带来近20款创新产品及方案：Halcyon Evolve 智能放疗平台全球首发，光子计数CT引导PCI方案中国首展，ARTIS genio floor 亚洲首发。诺华展示四大治疗领域、五大技术平台成果，多款为全球首个创新疗法；免疫新药 Ianalumab 中国首展，这是靶向B细胞的全人源单克隆抗体。罗氏迎来服务中国 100 周年，现场复刻百年前老药房，近百件展品首展首秀，吉雷司群、佳罗华亮相。

跨国企业持续加码投资中国

拜耳与仙乐健康、九州通、若羽臣、上药控股签署战略合作。诺华在华推进100多个临床项目，2026年起新药注册100%全球同步；约15亿元昌平新厂区启动，约6亿元海盐放射配体基地2027年投产。罗氏投资20.4亿元的上海基地，是跨国药企首个在华大分子抗体本地化生产基地，将用于罗视佳生产。

文、图｜记者 何晶

译 | 郑书悦

审 | 肖凯欣